FDA OKs Ranibizumab for All Forms of Diabetic Retinopathy FDA OKs Ranibizumab for All Forms of Diabetic Retinopathy
The VEFG inhibitor had been approved just for diabetic retinopathy accompanied by diabetic macular edema, in addition to other eye disorders.FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 18, 2017 Category: Endocrinology Tags: Ophthalmology News Alert Source Type: news
FDA Approves Genentech ’s Lucentis (ranibizumab) for all Forms of Diabetic Retinopathy
South San Francisco, CA -- April 17, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 17, 2017 Category: Drugs & Pharmacology Source Type: news
Cardiovascular Safety of Ranibizumab for Diabetic Macular Edema Still Unclear Cardiovascular Safety of Ranibizumab for Diabetic Macular Edema Still Unclear
Uncertainty lingers about the cardiovascular safety of intravitreal ranibizumab injections for diabetic macular edema, a pooled analysis of clinical trials shows.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 12, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Opthea gets positive feedback from European regulatory groups for wet-AMD injection
Opthea (ASX:OPT) said today that it received positive feedback from meetings with the U.K.’s Medicines and Healthcare Products Regulatory Agency and Sweden’s Medical Products Agency over its OPT-302 therapy for the treatment of wet age-related macular degeneration.
The Australia-based company’s OPT-302 therapy consists of a soluble form of vascular endothelial growth factor receptor 3 that blocks the activity of 2 proteins that cause blood vessels to grow and leak. It is being evaluated in a phase 1/2 clinical trial in patients with wet AMD as a monotherapy and with ranibizumab, delivered as monthly intravitreal inje...
Source: Mass Device - March 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Regulatory/Clearance Wall Street Beat Opthea Source Type: news
Researchers develop micropump for patients with glaucoma
Researchers from the University of Southern California’s Roski Eye Institute developed a micropump that can be implanted directly into the eye and deliver a predetermined dose of the diabetic macular edema drug ranibizumab.
Current treatments for glaucoma are traditionally delivered using eye drops. But studies show that some patients stop taking their prescription glaucoma eye drops after 1 year, according to the team of researchers. Patients can be uncomfortable using the eye drops or they forget to consistently take their prescribed medication.
Get the full story at our sister site, Drug Delivery Business News.
...
Source: Mass Device - March 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Research & Development Replenish Inc Source Type: news
Lucentis (Ranibizumab Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 27, 2017 Category: Drugs & Pharmacology Source Type: news
Baseline Characteristics and Outcomes of Ranibizumab for DME Baseline Characteristics and Outcomes of Ranibizumab for DME
Data from this study provides insight into the patient characteristics and visual outcomes among those treated with ranibizumab injections for DME.The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 13, 2017 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
FDA Clears Ranibizumab for Myopic Choroidal Neovascularization FDA Clears Ranibizumab for Myopic Choroidal Neovascularization
Ranibizumab becomes the first FDA-approved anti-vascular endothelial growth factor therapy for mCNV.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 6, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
FDA approves Lucentis (ranibizumab injection) for myopic choroidal neovascularisation
Roche announced today that the US Food and Drug Administration (FDA) has approved Lucentis ® (ranibizumab injection) 0.5 mg for the treatment of patients with myopic choroidal neovascularisation (mCNV), a complication of severe near-sightedness that can lead to blindness. (Source: Roche Investor Update)
Source: Roche Investor Update - January 6, 2017 Category: Pharmaceuticals Source Type: news
FDA Approves Genentech ’s Lucentis (ranibizumab) for Myopic Choroidal Neovascularization
South San Francisco, CA -- January 5, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis ® (ranibizumab injection) 0.5 mg for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 5, 2017 Category: Drugs & Pharmacology Source Type: news
Novartis eye drug franchise hit by failed Fovista studies
ZURICH (Reuters) - Novartis's bid to bolster its eye drug portfolio suffered a setback on Monday when it announced combining Lucentis with Fovista in patients with neovascular age-related macular degeneration (nAMD) did not produce better outcomes than treatment with Lucentis alone. (Source: Reuters: Health)
Source: Reuters: Health - December 12, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Ranibizumab Effective for Pigment Epithelial Detachment Ranibizumab Effective for Pigment Epithelial Detachment
Low-dose ranibizumab is effective in treating pigment epithelial detachment in patients with neovascular age-related macular degeneration, a post hoc analysis of the HARBOR study suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 30, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Predicting Anti-VEGF Response in Diabetic Macular Edema Predicting Anti-VEGF Response in Diabetic Macular Edema
Response after 12 weeks of ranibizumab therapy can predict long-term outcomes in diabetic macular edema, a post hoc analysis suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Is Anti-VEGF Monotherapy Best for Diabetic Macular Edema? Is Anti-VEGF Monotherapy Best for Diabetic Macular Edema?
One of the predictors of visual improvement in patients with diabetic macular edema is ranibizumab monotherapy, an analysis of the RESTORE data shows, but not everyone agrees with the findings.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Laser vs Drugs for Diabetic Retinopathy: Mostly a Toss-Up (CME/CE)
(MedPage Today) -- But Lucentis favored for some outcomes in randomized trial (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - September 6, 2016 Category: Opthalmology Source Type: news
